These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29707600)

  • 1. Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.
    Poletti V; Charrier S; Corre G; Gjata B; Vignaud A; Zhang F; Rothe M; Schambach A; Gaspar HB; Thrasher AJ; Mavilio F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():257-269. PubMed ID: 29707600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
    Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
    N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
    Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
    Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells.
    Brault J; Liu T; Liu S; Lawson A; Choi U; Kozhushko N; Bzhilyanskaya V; Pavel-Dinu M; Meis RJ; Eckhaus MA; Burkett SS; Bosticardo M; Kleinstiver BP; Notarangelo LD; Lazzarotto CR; Tsai SQ; Wu X; Dahl GA; Porteus MH; Malech HL; De Ravin SS
    Front Immunol; 2022; 13():1067417. PubMed ID: 36685559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
    Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
    Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
    van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
    Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
    N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
    Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
    Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
    De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
    Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
    Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
    PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
    Blanco E; Izotova N; Booth C; Thrasher AJ
    Front Immunol; 2020; 11():608653. PubMed ID: 33329605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: A Novel IL2RG Frame-Restoring Rescue Mutation Mimics Early T Cell Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation in a Patient With X-SCID.
    Steininger J; Leiss-Piller A; Geier CB; Rossmanith R; Elfeky R; Bra D; Pichler H; Lawitschka A; Zubarovskaya N; Artacker G; Matthes-Leodolter S; Eibl MM; Wolf HM
    Front Immunol; 2021; 12():644687. PubMed ID: 33959125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
    Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
    Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.
    Schiroli G; Ferrari S; Conway A; Jacob A; Capo V; Albano L; Plati T; Castiello MC; Sanvito F; Gennery AR; Bovolenta C; Palchaudhuri R; Scadden DT; Holmes MC; Villa A; Sitia G; Lombardo A; Genovese P; Naldini L
    Sci Transl Med; 2017 Oct; 9(411):. PubMed ID: 29021165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
    Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
    Gaspar HB; Parsley KL; Howe S; King D; Gilmour KC; Sinclair J; Brouns G; Schmidt M; Von Kalle C; Barington T; Jakobsen MA; Christensen HO; Al Ghonaium A; White HN; Smith JL; Levinsky RJ; Ali RR; Kinnon C; Thrasher AJ
    Lancet; 2004 Dec 18-31; 364(9452):2181-7. PubMed ID: 15610804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy of X-linked severe combined immunologic deficiency (SCID-X1)].
    Hacein-Bey S; Gross F; Nusbaum P; Yvon E; Fischer A; Cavazzana-Calvo M
    Pathol Biol (Paris); 2001 Feb; 49(1):57-66. PubMed ID: 11265225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.
    Throm RE; Ouma AA; Zhou S; Chandrasekaran A; Lockey T; Greene M; De Ravin SS; Moayeri M; Malech HL; Sorrentino BP; Gray JT
    Blood; 2009 May; 113(21):5104-10. PubMed ID: 19286997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.